Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Hueber W., Sands BE., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins PDR., Wehkamp J., Feagan BG., Yao MD., Karczewski M., Karczewski J., Pezous N., Bek S., Bruin G., Mellgard B., Berger C., Londei M., Bertolino AP., Tougas G., Travis SPL.